secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001193125-25-178504
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Q2 net loss $26.9M; TSHA-102 pivotal trial site activation begun, enrollment Q4 2025
--------------------------------------------------------------------------------

- Cash $312.8M after $230M follow-on offering; runway extended into 2028.
- Net loss $26.9M ($0.09/share) vs $20.9M ($0.09) in Q2 2024.
- REVEAL pivotal trial site activation commenced; FDA and Health Canada feedback received.
- 100% response rate on primary endpoint in Part A; no treatment-related SAEs or DLTs in 12 patients.
- New supplemental clinical data from Part A expected in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/0001193125-25-178504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/d51118d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-178504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer